agilon health (AGL) Stock
$113.07
−0.62% Close Nov 6
Open interactive chartAGL stock price and performance
AGL stock closed at $113.07 on Nov 6, 2026. The tables below use that final daily session.
- Last close
- $113.07
- Day range
- $106.34 to $116.77
- 52-week range
- $7.48 to $133.04
- From 52-week high
- −15.0%
- Average volume (50 days)
- 221,506
- 1 week
- +33.6%
- 1 month
- +33.5%
- 3 months
- +16.8%
- Year to date
- +556.4%
- 1 year
- +499.8%
- 3 years
- −73.2%
- 5 years
- −81.5%
Is AGL stock in an uptrend?
Yes, AGL stock is in an uptrend: 1 of the 2 Daily Pivot Breakout momentum filters is active, although it does not meet the Minervini Trend Template criteria. Price is above its 200-day moving average.
- Daily Pivot momentum filters
- 1 of 2 active
- 100-day ROC
- −0.2% filter at 40%: off
- 100-day EMA slope
- +71.7% filter at 25%: active
- Trend state
- Uptrend
- Minervini Trend Template
- Not met on the latest scan
- 50-day average
- Above
- 150-day average
- Above
- 200-day average
- Above
- 200-day slope (1 month)
- +12.29%
- ATR (14) % of price
- 6.79%
Momentum filters from the Daily Pivot Breakout indicator: 100-day rate of change and 100-day EMA slope, each against its minimum.
Is AGL stock in a Stage 2 uptrend?
Yes, AGL stock is in a Stage 2 uptrend by our Weinstein stage analysis: its price is above a rising 30-week moving average and it is outperforming SPY.
- Weinstein stage
- Stage 2 (advancing)
- 30-week SMA
- $88.57
- 30-week slope (4 weeks)
- +13.79%
- Mansfield RS vs SPY
- 96.82
- Weeks in Stage 2
- 1
Weinstein stage analysis uses weekly closes against the 30-week moving average and Mansfield relative strength versus SPY. See the free Stage 2 stocks screener.
AGL support and resistance levels
| Level | Price | From close |
|---|---|---|
| 9-day EMA | $98.08 | −13.3% |
| Daily Pivot resistance (pivot high) | $94.37 | −16.5% |
| 21-day EMA | $92.72 | −18.0% |
| 30-week SMA | $88.57 | −21.7% |
| 50-day SMA | $88.28 | −21.9% |
| 150-day SMA | $84.45 | −25.3% |
| Latest Daily Pivot low | $72.16 | −36.2% |
| 200-day SMA | $66.85 | −40.9% |
Levels above the close act as resistance, levels below as support. Last close $113.07.
AGL breakout and scanner signals
| Scanner | Last signal (free view, 5 sessions late) | Past year |
|---|---|---|
| VCP | None in the last year | 0 |
| RSI Divergence | Sep 11, 2026 | 3 |
| Weinstein Stage Analysis | Oct 19, 2026 | 113 |
| Daily Pivot Breakout | Jul 17, 2026 | 2 |
| Minervini Trend Template | Aug 5, 2026 | 31 |
| Episodic Pivot | May 7, 2026 | 1 |
| Ichimoku TK cross | Oct 15, 2026 | 4 |
| 9/21 EMA cross | Oct 19, 2026 | 4 |
| Golden / Death Cross | May 13, 2026 | 1 |
| RS Rating | Oct 22, 2026 | 116 |
AGL seasonality by month
- Jan+7.9%60% up
- Feb−2.5%40% up
- Mar+5.9%60% up
- Apr+42.8%40% up
- May+33.4%67% up
- Jun+6.3%83% up
- Jul−2.6%50% up
- Aug−17.1%0% up
- Sep−7.5%33% up
- Oct−12.0%33% up
- Nov−19.8%0% up
- Dec+5.9%60% up
Average monthly return over 5+ years of stored daily closes, and the share of years each month closed higher.
AGL earnings history
| Reported | EPS estimate | EPS actual | Surprise |
|---|---|---|---|
| Nov 4, 2026 | $-1.47 | $1.97 | +234.0% |
| Aug 5, 2026 | $0.27 | $2.15 | +696.3% |
| May 22, 2026 | $1.34 | $1.78 | +32.8% |
| May 6, 2026 | $0.93 | $2.32 | +149.5% |
| Feb 25, 2026 | $-6.85 | $-8.95 | −30.7% |
AGL bull and bear case
What looks strong
- Stage 2 uptrend by our Weinstein stage analysis scanner.
- 1 of 2 Daily Pivot momentum filters is active (100-day ROC -0.2%, 100-day EMA slope 71.7%).
- The 50, 150 and 200-day averages are stacked in uptrend order.
- Price is above a rising 200-day moving average.
- Price closed above its Daily Pivot resistance level.
What looks weak
- Does not meet the Minervini Trend Template on the latest scan.
- Net income over the last 12 months is negative.
- Beta is 3.11, so the stock has moved much more than the market.
Drawn only from the data on this page. Not a recommendation.
AGL news and SEC filings, last 30 days
Source: SEC EDGAR.
AGL insider trading and risks
Risk flags from the data
- Net income over the last 12 months is negative.
- Beta is 3.11, so the stock has moved much more than the market.
Insider trades: SEC Form 4 open-market purchases and sales.
AGL valuation and fundamentals
- Market cap
- $1.90B
- Enterprise value
- $1.70B
- P/E (trailing)
- -4.8
- P/E (forward)
- 48.0
- PEG
- 0.04
- Price to sales
- 0.32
- Price to book
- 6.78
- EV to EBITDA
- -19.8
- Gross margin
- +7.2%
- Operating margin
- +1.8%
- Profit margin
- −1.5%
- Return on equity
- −36.2%
- Revenue (TTM)
- $6.00B
- Revenue growth (quarter, y/y)
- +5.9%
- Cash
- $239.8M
- Debt
- $33.4M
- Beta
- 3.11
| Fiscal year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | $5.93B | −$391.3M | −$105.8M |
| 2024 | $6.06B | −$260.1M | −$75.2M |
| 2023 | $4.32B | −$262.8M | −$197.0M |
| 2022 | $2.39B | −$106.9M | −$118.9M |
AGL dividends and splits
- Dividend yield
- 0.00%
Stock splits: 1-for-25 split on Mar 31, 2026.
Who owns AGL?
- Shares outstanding
- 16.8M
- Float
- 10.9M
- Held by insiders
- +5.0%
- Held by institutions
- +98.5%
- Short interest (% of shares)
- +8.5%
- Days to cover
- 3.9
What does agilon health, Inc. do?
- CEO
- Mr. Timothy Patrick O'Rourke
- Employees
- 856
- Headquarters
- Westerville, OH, United States
- Website
- agilonhealth.com
